Medical Expenditures Associated With Hypertension in the U.S., 2000-2013

Donglan Zhang, Guijing Wang, Ping Zhang, Jing Fang, Carma Ayala, Donglan Zhang, Guijing Wang, Ping Zhang, Jing Fang, Carma Ayala

Abstract

Introduction: Trends of prevalence, treatment, and control of hypertension have been documented in the U.S., but changes in medical expenditures associated with hypertension over time have not been evaluated. This study analyzed these expenditures during 2000-2013 among U.S. adults.

Methods: Data from the Medical Expenditure Panel Survey were analyzed in 2016. The study population was non-institutionalized men and non-pregnant women aged ≥18 years. Hypertension was defined as ever been diagnosed with hypertension or currently taking antihypertensive medications. Medical expenditures included all payments to medical care providers. Expenditures associated with hypertension were estimated by two-part regression models and adjusted into 2015 U.S. dollars. Controlling variables included sociodemographic characteristics, marital status, insurance, region, smoking status, weight status, health status, and comorbidities. Trends were analyzed using joinpoint method.

Results: Total per-person annual expenditures associated with hypertension in 2000-2001 ($1,399) were not significantly different from those in 2012-2013 ($1,494) (average annual percent change [AAPC]= -0.6%, p=0.794), but annual national spending increased significantly from $58.7 billion to $109.1 billion (AAPC=8.3%, p=0.015), mainly because of the increase in the number of people treated for hypertension. Per-person outpatient payments were 22.7% higher in 2012-2013 than in 2000-2001 ($416 vs $322, p<0.05; AAPC=0.8%, p-trend=0.826). Payments for prescription medications took up a larger proportion of the medical expenditures associated with hypertension, compared to payments for outpatient or other services (33%-46%).

Conclusions: During 2000-2013, annual national medical expenditures associated with hypertension increased significantly. Preventing hypertension could alleviate hypertension-associated economic burden.

Conflict of interest statement

No financial disclosures were reported by the authors of this paper.

Copyright © 2017 American Journal of Preventive Medicine. All rights reserved.

References

    1. Bauer UE, Briss PA, Goodman RA, Bowman BA. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. Lancet. 2014;384(9937):45–52. .
    1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290(2):199–206. .
    1. Yoon SS, Fryar CD, Carroll MD. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS Data Brief. 2015;(220) .
    1. Yoon SS, Gu Q, Nwankwo T, Wright JD, Hong Y, Burt V. Trends in blood pressure among adults with hypertension United States, 2003 to 2012. Hypertension. 2015;65(1):54–61. .
    1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–e603. .
    1. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126(17):2105–2114. .
    1. Agency for Healthcare Research and Quality. Statistical Brief #404: expenditures for hypertension among adults age 18 and older 2010: estimates for the U.S. civilian noninstitutionalized population. 2013 . Published.
    1. D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care the Framingham Heart Study. Circulation. 2008;117(6):743–753. .
    1. Wang G, Yan L, Ayala C, George MG, Fang J. Hypertension-associated expenditures for medication among U.S. adults. Am J Hypertens. 2013;26(11):1295–1302. .
    1. Wang G, Fang J, Ayala C. Hypertension-associated hospitalizations and costs in the United States, 1979–2006. Blood Press. 2014;23(2):126–133. .
    1. Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 2003;326(7394):845. .
    1. Zuvekas SH, Olin GL. Validating household reports of health care use in the medical expenditure panel survey. Health Serv Res. 2009;44(5, pt 1):1679–1700. .
    1. Agency of Healthcare Research and Quality. Using appropriate price indices for analyses of health care expenditures or income across multiple years. . Accessed August 2016.
    1. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. .
    1. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461–494. .
    1. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17(3):247–281. .
    1. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation?: comparing methods of modeling Medicare expenditures. J Health Econ. 2004;23(3):525–542. .
    1. MEPS-HC summary data tables: technical notes. Rockville, MD: Agency for Healthcare Research and Quality; 2013. .
    1. Clabaugh G, Ward MM. Cost of illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health. 2008;11(1):13–21. .
    1. National Cancer Insititute, Division of Cancer Control and Population Science. Joinpoint Trend Analysis Software. 2016 Version 4.3.1.0. . Published.
    1. Trogdon JG, Murphy LB, Khavjou OA, et al. Costs of chronic diseases at the state level: the Chronic Disease Cost Calculator. Prev Chronic Dis. 2015;12:E131. .
    1. Hartman M, Martin AB, Benson J, Catlin A, Team NHEA National health spending in 2011: overall growth remains low, but some payers and services show signs of acceleration. Health Aff (Millwood) 2013;32(1):87–99. .
    1. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2571. .
    1. Branstetter LG, Chatterjee C, Higgins M. (NBER Working Paper No 17188).Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry. 2011 Jun; Published.
    1. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood) 2011;30(1):91–99. .
    1. Cuckler GA, Sisko AM, Keehan SP, et al. National health expenditure projections, 2012–22: slow growth until coverage expands and economy improves. Health Aff (Millwood) 2013;32(10):1820–1831. .
    1. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens. 2000;14(2):83–90. .
    1. Lee H-Y, Oh B-H. Aging and arterial stiffness. Circ J. 2010;74(11):2257–2262. .
    1. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief. 2013;(133):1–8.
    1. Albright K, Boehme A, Sen B, et al. Stroke severity in men and women: what proportion of the disparity can be explained by differences in cardiovascular risk factors? Stroke. 2014;45(suppl 1):AWP121.
    1. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States. Circulation. 2011;123(8):933–944. .
    1. Lau DT, Kasper JD, Potter D, Lyles A, Bennett RG. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165(1):68–74. .

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever